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ABSTRACT
Polycystic ovary syndrome (PCOS) is one of the most common causes of infertility in women of reproductive age. The aim of the 
study was to determine the level of apelin, insulin resistance (IR), transforming growth factor beta 1 (TGF-β1), and endoglin in women 
with polycystic ovary syndrome. Fifty PCOS patients and 40 non-PCOS infertile patients were recruited. The fasting serum levels of 
folliclestimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), prolactin, fasting blood glucose, insulin, and apelin at 
the early follicular phase were measured. Levels of apelin, LH, LH/FSH, T, and fasting insulin, as well as homeostatic model assessment 
of IR (HOMA-IR) in PCOS patients, were significantly higher than in the control group. Correlation analysis showed that apelin level 
was positively correlated with body mass index and HOMA-IR. Apelin levels and TGF-β1 were significantly increased in PCOS patients 
while show decrease levels of endoglin.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine disease affecting women of reproductive age. The prevalence of PCOS varies according to the 
diagnostic criteria used, with estimates ranging from 9% in 
women of reproductive age, according to NIH criteria, up to 
18%, with the Rotterdam criteria.[1]
It is primarily characterized by ovulatory dysfunction 
and hyperandrogenism,[2] but the clinical presentation is 
heterogeneous and patients may present some of various signs 
and symptoms. This heterogeneity seems to be modulated 
by multiple factors such as prenatal androgen exposure, 
nutritional status in the uterus, genetic factors, and ethnicity, 
insulin resistance (IR) of puberty and/or exaggerated 
adrenarche and changes in body weight.[3] Environmental 
factors, such as obesity, appear to exacerbate the underlying 
genetic predisposition. Concerning ethnicity, the presence of 
hirsutism is less frequent in Asian patients (around 10%), 
compared to Caucasian ones (70%).[4]
Obesity is a prevalent characteristic of PCOS, ranging from 
12.5% to 100%, with a pooled estimated prevalence of 49%, as 
shown by a recent meta-analysis.[5] The presence of obesity may 
exacerbate the metabolic and reproductive disorders associated 
with the syndrome, including IR, dyslipidemia, and metabolic 
syndrome.[6] A meta-analysis[7] has shown that women with PCOS 
have higher levels of triglycerides (TG), low-density lipoprotein 
(LDL)-cholesterol and total cholesterol (TC), and lower 
high-density lipoprotein (HDL)-cholesterol levels compared 
with control women, regardless of body mass index (BMI). In 
addition, PCOS women present higher risk for type 2 diabetes. 
PCOS is also associated with a clustering of cardiovascular risk 
factors.[8] However, there is no definitive evidence for increased 
cardiovascular events, nor data showing that PCOS alone leads 
to increased cardiovascular risk independent of associated 
risk factors. In fact, more rigorous cohort studies of long-
term cardiovascular outcomes and clinical trials of risk factor 
modification are required for women with PCOS.
In addition, evidence suggests clinical phenotypes are 
related with different metabolic risks. In this sense, IR seems 
to be a specific feature of the classic phenotype and, to a lesser 
extent, of the ovulatory phenotype. Non-hyperandrogenic 
phenotype behaves as a separate group that is metabolically 
similar to non-PCOS women.[7]
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Adipose tissue is considered not only a storage tissue 
but also aproper endocrine organ, metabolically active.[6] IR 
is considered the main pathogenic factor in the background 
of increased metabolic disturbances in women with PCOS 
which can explain hyperandrogenism, menstrual irregularity, 
and other metabolic manifestations seen in this disease.[7] 
However, it is not a diagnostic criterion for PCOS.[8]
Obesity alters the expression, circulating levels, and signaling 
mechanisms of adipose-secreted factors and these changes 
have been linked to the development of IR, type 2 diabetes, 
dyslipidemia, atherosclerosis, cancer, and other diseases.[9]
Apelin is an endogenous cytokine,[10] an adipokine,[11] a 
regulatory peptide,[12] and a neuropeptide[13] that has been 
linked to obesity and IR.
Apelin is a 36-amino acid peptide (AP-36) generated from 
a larger precursor the 77-amino acid proapelin. The human 
preproapelin gene is located on chromosome X at locus 
Xq25-q26.1.[10]
Collected data from both the clinical and basic settings 
show that AP (1) correlates with states of IR and obesity, (2) 
stimulates glucose utilization, (3) decreases insulin secretion, 
and (4) negatively regulates catecholamine-mediated lipolysis. 
AP seems to be a key regulator in glucose and lipid metabolism 
and may be associated with IR and possibly implicated in 
PCOS which is known to be associated with increased IR[14] 
and from hence the possible link to apelin levels.
Endoglin (sEng)/CD105 is a transmembrane auxiliary 
receptor for transforming growth factor beta (TGF-b) it works as a 
non-signaling coreceptor of the TGF-b modulating its responses. 
There are a number of reports suggesting that soluble endoglin 
may be regarded as a biomarker of endothelial dysfunction, 
for instance, atherosclerosis, hypercholesterolemia,[15] Type 2 
diabetes mellitus (T2DM), and hypertension.[16]
TGF-b1 is a multifunctional cytokine that is produced by 
a variety of cells and its level dysregulated in women with 
PCOS, which might play a role in the pathophysiology of 
this syndrome. Substantial evidences implicate that TGF-b1 
activation is closely associated with endothelial dysfunction 
and hypertension.[17] There is scattered evidence for the 
association between TGF-b1, visceral adiposity, metabolic 
syndrome, nonalcoholic fatty liver disease, and T2DM.[15]
METHODS
This case–control study was conducted at the obstetrics 
and gynecology department in medical city in Baghdad. It 
was conducted on ninety women during the period from 
March 2018 to September 2018. These were divided into 
two groups: Group I: Fifty overweight and obese women 
with PCOS (PCOS group) and Group II: Forty overweight 
and obese women without PCOS (non-PCOS group). The 
recruited women were counseled and written informed 
consent was obtained from each woman before her 
participation in the study.
Diagnosis of PCOS was made according to the Rotterdam 
criteria[18] in the presence of at least two of the following: (a) 
Oligomenorrhea and/or anovulation, (b) biochemical and/or 
clinical hyperandrogenism, and (c) ultrasound appearance of 
polycystic ovaries (multiple cysts >12 in number of 2–9 mm 
size),[3] BMI P 25 kg/m2.
Samples were obtained between days 2 and 5 of normal 
spontaneous or withdrawn menstrual cycle. Blood allowed to 
clot for 10–20 min at room temperature and centrifuged at 
(2000–3000 RPM) for approximately 20 min to separate the 
serum from the cells.
2 ml serum was stored at _20_c until the time of AP-36 
and hormonal profile assay. Hormonal evaluation included a 
baseline plasma determination of luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), dehydroepiandrosterone 
sulfate, TSH, E2, and free testosterone. All hormones were 
measured by radioimmunoassay methods using commercial 
kits (DSL Inc., Webster, Texas, USA). The fasting insulin was 
measured by radioimmunoassay methods using commercial 
kits (the intra and inter-assay coefficients of variation were 
1.98% and 0.84%, respectively) (Immunospect Corporation, 
Owensmouth Ave, Canoga Park, CA). Fasting glucose was 
measured by the glucose oxidase method (Yellow Springs 
Instrument, Yellow Springs, OH, USA). TC, TG, and HDL were 
assayed using fully automated clinical chemistry autoanalyzer 
system Konelab 20i LDL was calculated according to 
Friedewald formula: LDL = TC−(TG/5+HDL).[19] IR was 
calculated by homeostatic model assessment (HOMA) using 
the following formula: HOMA-IR = ([FG in mg/dL_0.05551]_
FI in mU/ml)/22.5. A diagnosis of IR established for HOMA-IR 
values >2.71 nmol_mU/l[20] equal (FG in mg/dL_FI in mU/
ml)/405. IR was diagnosed according to the FG to FI ratio. If 
a participant’s FG/FI was 4.5 or less, she would be classified 
as being IR and if her FG/FI was >4.5, she would be classified 
as being non-IR.[21]
RESULTS
The results obtained are shown in Table 1 and Table 2.
The group Mean±SD P-value
PCOS Control
Age (year) 28.28±5.11 33.27±6018 0.00033*
BMI (kg/m2) 32.16±2.28 29.07±1.40 0.00001*
Hirsutism score 13.79±1.2 5.33±0.75 0.00001*
TGF-β1 (ng/ml) 19.34±2.73 12.29±1.19 0.00001*
Table 1: The mean and SD of biochemical and immune markers level in the patients group and healthy control group
(Contd...)
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Table 2: Correlation between apelin, transforming growth factor beta, and endoglin with other parameters in the PCOS disease patients
The group Correlation coefficient (r)
TGF-β1 (ng/ml) s-endoglin ng/ml Apelin (pg/ml)
Age (year) 0.0917 −0.0948 −0.1572
BMI (kg/m2) 0.3333 0.0379 0.0353
Hirsutism score −0.2653 0.0955 −0.1134
TGF-β1 (ng/ml) - 0.2007 0.1903
s-endoglin ng/ml 0.2007 - −0.0502
Apelin (pg/ml) 0.1903 −0.0502 -
Fasting plasma glucose (mg/dl) 0.1447 −0.0654 −0.0531
Insulin (IU/ml) −0.0978 −0.0906 0.0132
HOMA 0.1547 −0.1586 0.1233
Prolactin (pg/ml) −0.1503 0.3305 −0.223
FSH (mIU/ml) −0.0841 −0.0611 −0.1269
LH (mIU/ml) −0.0413 0.0798 0.2071
SHBG (nmol/L) 0.2081 −0.189 0.198
DHEA-s (mg/ml) −0.1289 −0.0002 −0.1991
Total testosterone (ng/ml) 0.0887 −0.1985 −0.0872
Free testosterone (pg/ml) 0.1543 −0.4447 0.0568
h-CRP (μg/ml) 0.0484 −0.1559 −0.0966
Cholesterol mg/dl −0.1114 0.0285 0.323
Triglyceride (mg/dl) 0.354 0.1584 0.0839
HDL (mg/dl) −0.1063 0.1887 −0.0182
LDL (mg/dl) −0.1063 −0.1289 0.43
*(P<0.05), **(P<0.01), NS: Non-significant. PCOS: Polycystic ovary syndrome, BMI: Body mass index, TGF: Transforming growth factor, HOMA: Homeostatic 
model assessment, FSH: Follicle-stimulating hormone, LH: Luteinizing hormone, SHBG: Sex hormone-binding globulin, DHEA: Dehydroepiandrosterone, h-CRP: 
High sensitivity C-reactive protein, HDL: High-density lipoprotein, LDL: Low-density lipoprotein
The group Mean±SD P-value
PCOS Control
s-endoglin ng/ml 3.37±1.25 5.02±1.34 0.00001*
Apelin (pg/ml) 220.92±16.87 367.05±37.87 0.00001*
Fasting plasma glucose (mg/dl) 94.76±20.71 90.0±14.7 0.00001*
Insulin (IU/ml) 18.76±4.33 12.0±6.5 0.00001*
HOMA 2.44±1.16 1.72±1.01 0.001375*
Prolactin (pg/ml) 13.71±1.25 13.14±1.56 0.02867*
FSH (mIU/ml) 7.04±1.13 6.03±1.32 0.000099*
LH (mIU/ml) 12.13±1.77 5.88±1.2 0.00001*
SHBG (nmol/L) 30.25±2.51 54.12±4.3 0.00001*
DHEA-s (mg/ml) 2.21±0.59 0.95±0.3 0.00001*
Total testosterone (ng/ml) 0.91±0.41 0.59±0.22 0.000017*
Free testosterone (pg/ml) 2.65±0.66 1.064±0.26 0.00001*
h-CRP (μg/ml) 5.75±1.34 2.3±0.7 0.00001*
Cholesterol mg/dl 172.6±49.9 166.0±27.3 0.254423 NS
Triglyceride (mg/dl) 155.86±34.69 103.0±32.2 0.00001*
HDL (mg/dl) 39.14±10.09 39.92±7.15 0.347843 NS
LDL (mg/dl) 103.42±36.31 101.9±24.2 0.413274 NS
*(P<0.05), **(P<0.01), NS: Non-significant. PCOS: Polycystic ovary syndrome, BMI: Body mass index, TGF: Transforming growth factor, HOMA: Homeostatic 
model assessment, FSH: Follicle-stimulating hormone, LH: Luteinizing hormone, SHBG: Sex hormone-binding globulin, DHEA: Dehydroepiandrosterone, h-CRP: 
High sensitivity C-reactive protein, HDL: High-density lipoprotein, LDL: Low-density lipoprotein
Table 1: (Continued)
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DISCUSSION
PCOS is one of the most common causes of infertility in 
women of reproductive age. IR is a main pathophysiologic 
feature in these patients.[2] Apelin (APLN) is a recently 
discovered adipokine involved in the regulation of various 
metabolic functions. Its receptor, APLNR, is expressed in 
reproductive tissues; however, its role in human ovarian cells 
is unknown. PCOS patients are more vulnerable to develop 
diabetes, cardiovascular diseases, and metabolic syndrome.[3] 
IR is prevalent in women with PCOS independently of obesity 
and is critically involved in reproductive and metabolic 
complications of the syndrome.[10]
Several tests have been developed to measure IR, some 
very reliable but complex like the hyperinsulinemic euglycemic 
glucose clamp and others less precise but easier and less 
invasive like HOMA-IR.[22] New markers are needed to reach a 
more reliable assessment of IR.
To date, several surrogate markers have been proposed 
in literature to facilitate and improve the determination of 
IR. Many new proteins are strongly involved with PCOS 
physiopathology and IR such as some adipocytokines 
(adiponectin, visfatin, vaspin, and apelin), copeptin, irisin, 
PAI-1, and zonulin. Many other proteins have been proposed 
as potential new markers of IR in PCOS such as resistin, leptin, 
retinol-binding protein 4 (RBP4), kisspeptin, and ghrelin, but 
their role is still controversial.[14]
Adipose tissue is implicated in the secretion of several 
hormones such as adiponectin, resistin, leptin, visfatin, apelin, 
and RBP4 called adipocytokines that are involved in energy 
homeostasis and metabolism.[11]
Apelin is a peptide isolated from bovine stomachs, but 
it is expressed in several other organs and also in visceral 
and subcutaneous tissues.[4] In our present study, however, 
serum apelin levels are significantly higher in PCOS women 
compared with controls. Moreover, we also observed that 
apelin level is significantly and positively correlated with 
BMI and HOMA-IR. Apelin was found to be higher in PCOS 
patients by Gören et al.[23] but without a significant correlation 
with HOMA-IR. Olszanecka-Glinianowicz et al.[18] reported an 
inverse association between apelin and glucose, insulin, and 
HOMA-IR values, supporting the role of apelin in the regulation 
of insulin sensitivity. Apelin levels were higher in non-obese 
PCOS patients, suggesting a compensatory mechanism for 
metabolic consequences of IR. Lower serum concentrations 
of apelin were found in PCOS subjects by Altinkaya et al.[19] 
with positive correlation with BMI, insulin, HOMA-IR, TG, 
and free testosterone, speculating that apelin can be used 
as a marker for insulin sensitivity. Conversely, Sun et al.[20] 
observed significantly enhanced apelin concentration in PCOS 
patients with positive association with BMI and HOMA-IR; 
treatment with drospirenone-ethinylestradiol plus metformin 
improved IR and apelin levels. Discrepant findings among 
the published studies may be attributed to the differences in 
ethnicity, age, study design, sample size, genetic characteristics 
of populations, and assessment methodology.
The increase of LH level probably plays an important 
role in the pathological mechanism of the higher androgens 
production in the ovaries, which can interfere with the 
maturation of the oocyte.[21] In the present study, the serum 
LH levels are significantly higher, while FSH level is lower in 
PCOS women compared with controls. These results further 
confirm that high LH level and relative insufficiency of FSH are 
the characteristics of PCOS.
In line with our results, Tal et al. found increased TGF-b1 
and decreased sEng in PCOS. These data suggest that increased 
TGF-b1 bioavailability may contribute to the pathogenesis of 
PCOS and its increased risk for ovarian hyperstimulation.[17] 
By contrast, the study conducted by Irani et al. found that 
sENG protein concentration was not different between PCOS 
and non-PCOS control group at baseline.[15] Women with 
PCOS have abnormal increase in TGF-b1 bioavailability (TGF-
b1/sENG) due to an increase in serum TGF-b1 and decrease in 
sENG levels.[17]
CONCLUSION
Polycystic ovary syndrome (PCOS) is a condition that affects a 
woman’s hormone levels.
Levels of TGF β1, LH, LH/FSH, T, and, as well as homeostatic 
model assessment of IR (HOMA-IR) in PCOS patients, were 
significantly higher than in the control group, while show 
decrease levels of Apelin and endoglin levels.
Therefore the correlation analysis showed that apelin level 
was negatively correlated with body mass index (BMI) and 
HOMA-IR.
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